CINJ 050703: A Phase Ib open-label, two-arm, dose-finding study of E7389 in combination with carboplatin in patients with solid tumours.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Carboplatin (Primary) ; Eribulin (Primary)
Indications Anal cancer; Colorectal cancer; Gynaecological cancer; Lung cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
Focus Adverse reactions
Sponsors Eisai Inc; Eisai Medical Research

24 May 2016 According to Eisai media release, data of this trial will be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), in June 2016.
13 Jul 2012 Status changed from recruiting to discontinued as reported by Clinical Trials Registry - India.
03 May 2011 Planned end date changed from 1 Jun 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com